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Why are so many adolescent girls becoming pregnant even
though contraception is available? What is the best technique for
repairing the congenital heart defects that still kill many newborns?
Is it possible to develop a drug that will slow or stop progression of
brain tumors in children? These questions are among those being
asked today by researchers.
Although presumably everyone wishes that these and other ques-
tions had answers, the notion of finding answers by performing re-
search on adolescents and children, especially infants, still meets
with strong resistance in some segments of our society.' Often this
resistance is unwarranted. For instance, if a two-year-old boy needs
a haircut, his mother takes him to a barbershop, sits him in a chair,
and regardless of objection, forces him to get a haircut. Few, if any,
advocates of children's rights would consider this haircut a threat to
the child's welfare. If a medical researcher, in contrast, wants to
study children's hair and the same two-year-old is brought by the
same mother to have a piece of hair snipped by a physician instead
of a barber, some people would argue that the child's fundamental
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New Haven Hospital; Clinical Professor of Pediatrics (Law), Yale University School of
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1. Research is a class of activities solely designed to develop or contribute to gener-
alizable knowledge. Practice refers to a class of activities designed to enhance the well-
being of an individual.
By definition, research is never intended to benefit the particular subject. If benefit is
intended, the intervention is practice. The category of practice consists of two subsets.
"Customary practice" is the currently accepted method of treating the patient's prob-
lem. "Non-validated practice" may include the application of novel procedures or inter-
ventions performed in the course of rendering treatment.
For general reading on the legal, ethical, and regulatory aspects of research on human
subjects, see R.J. Levine, Ethics and Regulation of Clinical Research (2nd ed. 1986)
(Chapter Nine discusses research on children); Levine, Clarifying the Concepts of Re-
search Ethics, Hastings Center Report 21 (June 1979); J. Katz, Experimentation with
Human Beings 999-1011 (1972).
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rights are being violated, and that the child himself is being abused,
because he cannot give legally binding consent to the haircut.
2
Current federal regulations, which took effect in 1983,3 now per-
mit most, if not all, research that responsible pediatricians conceiva-
bly might wish to perform on children. Yet ethical objections from
some influential commentators continue to have a substantial nega-
tive effect on researcher interest and funding, particularly in the
area of pediatric drug development. The politicians, journalists,
and physicians who equate pediatric research with child abuse exert
a strong influence over researchers, who are often unaware or reluc-
tant to take advantage of the latitude permitted for research under
current regulations. As a result of this prejudice, internists are more
likely to do important low-level drug testing on adults than pediatri-
cians are to do similar testing on children. Many drug companies
seem hesitant to sponsor potentially beneficial pediatric research
because they fear tort liability and negative publicity.
Psychologists and sociologists are also often reluctant or unable
to study, among other subjects, the psychosocial causes of adoles-
cent pregnancy, the effects on adolescent behavior of providing con-
traceptives, and research on the prevalence and prevention of AIDS
among adolescents. Social prejudice against research on these criti-
cal adolescent issues stems from a fear not that the research will
threaten the physical health of the subjects, but that it will threaten
their spiritual health. Because such studies are viewed in some polit-
ical circles as fostering immoral adolescent behavior,4 they generate
little interest or funding.
The prejudice against medical and public health research on chil-
dren and adolescents means that even those research projects that
are valuable, responsible, and permissible under current federal
regulations are not being initiated-and children are suffering as a
result.
5
2. See, e.g., Langer, Medical Research Involving Children: Some Legal and Ethical
Issues, 36 Baylor L. Rev. 1, 28-34 (1984), for a defense of this argument.
3. 48 Fed. Reg. 9814-20 (Mar. 8, 1983).
4. 1 Risking the Future: Adolescent Sexuality, Pregnancy, & Childrearing 248-49
(1987) (discussion of public policy issues relating to research involving adolescents).
The same fears behind the public prejudice against research on adolescent sexual be-
havior also affect the provision of sex education for minors. See Editorial, New York
Times, Mar. 15, 1985, at 26, col. 1 (criticizing the tendency of many Americans to op-
pose sex education for their children out of reluctance to accept responsibility for the
"sexual revolution").
5. One glaring example is the failure to date of any drug company to test improve-
ments in the diptheria-pertussis-tetanus [D.P.T.I vaccine. At present, these shots occa-




Medical research on adult subjects cannot serve as an adequate
substitute for medical research on children. Children are physiolog-
ically quite different from adults in many medically significant ways.
Answers to biomedical or psychosocial questions about adult condi-
tions and behavior may not apply to children; in some cases, in fact,
drugs developed to treat a disease successfully in adults may do per-
manent harm to children with the same condition. For example, tet-
racycline is an antibiotic commonly prescribed for adults who have
many types of infections, but it can cause permanent tooth damage
if given to small children.
Moreover, lack of adequate research on children may actually en-
danger their health. For instance, because critics of research on
children argue that children should be "protected" from the "dan-
gers" of being research subjects, there have been few, if any, trials
of drugs on sick children. Consequently, few results are available to
establish boundary levels in children, making maximum dosages un-
certain. In addition, because new drugs may not be tested on chil-
dren in "Phase One" drug trials,6 a great many drugs, some of
which may be quite helpful in the treatment of children, are labeled
"Not for pediatric use" or "This drug has not been tested and ap-
proved for use on children and infants." Pediatricians treating sick
children with these drugs in the course of ordinary clinical practice
are in effect conducting drug trials, whether or not they consider
themselves researchers. When harm caused by these drugs occurs
outside the setting of a clinical trial, reports of their side effects may
be sporadic or delayed. Side effects may, in fact, go unrecognized
by physicians caring for sick children. Meanwhile, children all over
are so great that parents sometimes refuse to allow children to be vaccinated at all,
leaving them vulnerable to whooping cough. Testing on children to develop a safer
D.P.T. vaccine would be permissible under the current federal regulations, but corpo-
rate concerns about tort liability have sapped the incentive to initiate this valuable re-
search. As a result, to date no safer vaccine has been developed.
6. An "investigational drug" is one not yet approved for use by the federal Food and
Drug Administration [FDA]. In the process of drug development, the investigator must
submit basic scientific and animal data to the FDA. If the FDA finds the data satisfactory,
the developer receives an Investigational New Drug Application [INDI and may then
administer the drug to human subjects in trials.
"Phase One" trials are almost always conducted on healthy volunteers; they establish
the safety of the drug. "Phase Two" trials involve a very small number of patients with
the disease that the drug is designed to alleviate; they establish the efficacy of the drug.
"Phase Three" trials further establish the safety and efficacy of the drug by involving a
wider sample of patients and a larger number of physicians.
When these trials are completed, the developer then applies to the FDA for a New
Drug Application INDAI. If this is granted, the drug can be made available for prescrip-
tion by any licensed physician.
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the country may be having the same unrecognized problem, causing
some of them to be protected to death.
Adolescents suffer from the results of overprotection from re-
search as well. In the current political climate, in fact, psychosocial
research is considered as much, if not more, of a threat to their well-
being than medical research. Adolescents are certainly different
psychologically and socially from younger children and from adults,
and the results of research on them will differ from the results of
research on adults and children. We will never learn much more
about adolescents if researchers continue to be prevented or dis-
couraged from conducting research on them.
Such discouragement may take the form of hospital requirements
that researchers obtain parental permission before administering
questionnaires to adolescents about such subjects as their sexual
activities. Federal regulations, however, do not require parental in-
volvement in such cases, and with good reason. Troubled adoles-
cents will often refuse to participate in research studies if
participation will lead their families to find out about their
problems. Study of these problems will continue to be impossible
so long as there is a requirement for parental involvement.
In this Comment, I will examine concerns about experimentation
on children and adolescents and will show how they are addressed
by federal guidelines and local research review boards. I will argue
that, with some modification, existing regulations and protocols
provide ample safeguards for young subjects of medical research.
Medical researchers often misunderstand or ignore the latitude of-
fered by these guidelines, retarding our progress in understand-
ing-and solving-important health and social problems.
I. Concerns About Research on Children
A central issue in debates about experimentation on humans, par-
ticularly children, has been consent. Those who object to the use of
minors as research subjects often cite Supreme Court dicta in Prince
v. Massachusetts:
Parents may be free to become martyrs themselves but it does not fol-
low that they are free in identical circumstances to make martyrs of
their children before they have reached the age of full and legal discre-
tion when they can make the choices for themselves.
7




Some authorities, both legal and ethical, have taken the position
that a parent cannot give valid consent for any medical procedure
on a child that is not for the direct benefit of that child because the
child lacks the legal capacity to give consent. 8
Paul Ramsey, a noted ethicist, has asserted that even in the ab-
sence of risk, an unconsented touching is a moral wrong.9 Donald
T. Chalkley, former Director of the Office of Protection from Re-
search Risks of the then-Department of Health, Education and Wel-
fare, wrote in 1973, "A parent has no legal right to give consent for
the involvement of his child in an activity not for the benefit of that
child.""' Advocates of this view would rule out even harmless re-
search on children, not only research with the potential for harm.''
A. A "Worst Case" Scenario
Opponents of research on children were inflamed by the notori-
ous "Willowbrook Experiment" in the 1950s and 1960s. Willow-
brook is a large state institution, then overcrowded and
understaffed, for the severely retarded in New York City. Conditions
at the hospital were so filthy that hepatitis was endemic among its
patients. Researchers in the Willowbrook Experiment vaccinated
children on their admission to the hospital, then infected them with
a mild dose of hepatitis to test the effectiveness of the vaccine
against the disease. Most parents consented to this experiment on
their children when the researchers told them that the children,
even if not the subjects of experimentation, would inevitably de-
velop more serious cases of hepatitis once they mingled with the
institution's general population. 12
8. See, e.g., P. Ramsey, The Patient as Person 17 (1974); McCormick, Proxy Consent
in the Experimentation Situation, 18 Persp. in Biology & Med. 2 (Autumn 1974).
9. Ramsey, supa note 8, at 17.
10. Human Experimentation, Med. World News, June 8, 1973, at 41 (quoting
Chalkley).
II. The contrary view, that parents may consent to research if the minor is exposed
to no discernible risk, was presented as early as 1969 in an article inJAMA, the journal of
the American Medical Association, Curran & Beecher, Experimentation in Children, 210
JAMA 77 (1969). It was also the position taken by the American Academy of Pediatrics
in 1977, Comm. on Drugs, American Academy of Pediatrics, Guidelines for the Ethical
Conduct of Studies to Evaluate Drugs in Pediatric Populations, 60 Pediatrics 91 (July
1977), and by the American Medical Association in 1966, McCormick, supra note 8, at 4
(containing American Medical Association, Ethical Guidelines for Clinical Investigation,
Nov. 30, 1966 (unpublished)).
12. For further reading on the Willowbrook case, seeJ. Katz, supra note 1, at 1007-
10; DJ. & S.M. Rothman, The Willowbrook Wars (1984); Student Council, New York
Univ. School of Medicine, Proceedings of the Symposium on Ethical Issues in Human
Experimentation: The Case of Willowbrook State Hospital (1973).
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The adults who worked at Willowbrook and who were exposed
similarly to the disease, however, were never used as subjects.'
Standard sanitation procedures and isolation of those children suf-
fering from hepatitis could have cleared the institution of the dis-
ease. Although the vaccine proved to be a significant achievement
that subsequently saved countless lives, the researchers did not
know what harm might occur when they tested it on the Willow-
brook children.
When the Willowbrook research was published, many commenta-
tors felt that the physicians involved had violated ethical stan-
dards.' 4 Willowbrook became a symbol for the view that all
research on children presented ethical problems of such magnitude
that it should not be performed.
B. Contemporaty Protections Against Abuses
The serious ethical questions raised by the Willowbrook Experi-
ments have largely been resolved today by case law, state statutes,
and federal regulations against child abuse. Today courts would
presumably take a very cautious view of the validity of a parent's
consent to research conducted on a child if there were any element
of coercion involved in that consent, as there was in the Willow-
brook case. Admission to Willowbrook was at one point restricted
to children whose parents consented to their participation in the
hepatitis research projects. Due to the enormous burdens on a fam-
ily presented by a severely retarded child and the need to place
some of these children in institutions, no court today would uphold
parental consent under these conditions as free and voluntary. To-
day we assume that where admission to treatment facilities is re-
stricted to children whose parents agree to their participation in
research studies and where the children, if not admitted, would
otherwise be denied standard treatment for financial or other rea-
sons, the voluntary nature of parental consent to the research is
questionable.5
Although it was not an issue in the Willowbrook case, offering
payment to parents for allowing their child to participate as a re-
13. Ramsey, supra note 8, at 48.
14. See, e.g., Goldy, Experiments at the Willowbrook State School, I Lancet 749
(1971).
15. This dilemma does not occur in those rare situations in which the child suffers
from a condition for which there is no known treatment and the sole potential therapy
for his problem is available only as part of a study. In such cases, a parent who consents
to a child's admission to a hospital for non-validated therapy and research studies pre-




search subject would introduce another potentially coercive element
into a research design. 6 In the absence of an inherently coercive
element, such as extreme poverty, payment of adult volunteers for
their inconvenience, discomfort, and risk appears to be ethically ac-
ceptable and is clearly legally permissible. Offering payment to a
person for consenting to a procedure on behalf of another, espe-
cially a child, however, is now deemed ethically unacceptable.
Today most courts would hold that, even if there were a therapeu-
tic justification for a particular project using children as subjects, a
parent could not give valid permission for dangerous non-validated
therapy on a child where there was available a standard, effective,
and less potentially dangerous non-experimental therapy for treat-
ment of the child's complaint. As a hypothetical example, suppose a
physician noticed that highly toxic chemotherapy that was effective
against some form of childhood cancer but caused severe side ef-
fects also seemed to stop itching when the children undergoing can-
cer treatment encountered poison ivy. Whatever the therapeutic
justification might be, prescribing the chemotherapy instead of stan-
dard remedies to an otherwise healthy child with poison ivy would
be clearly unethical-and legally might constitute child abuse.
The problems for children have changed since the Willowbrook
era. Children are clearly protected by law from such excesses as
occurred at that institution. If parents today consented to, and phy-
sicians performed, a dangerous intervention where an effective and
demonstrably safer therapy existed, as they did at Willowbrook, they
would probably be found in violation not only of state, but also of
federal, law.
II. The Federal Regulatory Scheme
Federal regulations establish a set of requirements that protect
child research subjects from abuses while allowing all children to
benefit from research uses. The Report and Recommendations of
the National Commission for the Protection of Human Subjects of
Biomedical and Behavioral Research (the Commission), established
by the National Research Service Award Act of 1974,17 provided
recommendations for nearly all aspects of ethical standards for con-
16. Capron. Legal Considerations Affecting Clinical Pharmacological Studies in
Children, 21 Clin. Res. 141, 146 (1973).
17. Pub. L. No. 93-348, 88 Stat. 342 (codified as amended in scattered sections of 42
u.S.C.).
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ducting research on children.' 8 The Department of Health and
Human Services (HHS) incorporated these recommendations into
agency regulations (the Regulations) in 1983.19
The Regulations form a web of rules indicating the permissible
boundaries for government-sponsored or -funded research and for
research to be submitted to federal agencies. Most universities re-
quire that all research projects undertaken by faculty, staff, or stu-
dents, regardless of their funding sources, comply with the federal
regulatory scheme. Thus the Regulations function as a set of na-
tional ethical standards, affecting most major research conducted
today.
The Regulations, detailed in this section, took significant steps to-
ward expanding the role of necessary medical research on children
while providing careful protections for child research subjects. The
Regulations resolve, at least in theory, the dispute between those
who fear the harm of research on children and those who seek its
benefits. Unfortunately, the Regulations have not achieved this res-
olution in practice. If properly clarified and followed, though, I be-
lieve that they would achieve their purpose.
A. Minimal Risk Projects
In building the regulatory scheme, HHS endorsed the basic build-
ing-block rule of child research: The Department agreed to conduct
or fund research that poses no greater than "minimal risk" to chil-
dren. 20 Local Institutional Review Boards (IRBs) were required to
review all proposals for research on human subjects and to validate
the existence of adequate provisions for soliciting children's assent
and parental permission.
The Regulations do not provide a definition of "minimal risk,"
creating uncertainty for medical researchers and divergent stan-
dards among the various IRBs. Other federal guidelines clearly de-
fine minimal risk as "those [risks] ordinarily encountered in daily
life or during the performance of routine physical or psychological
examinations or tests." 2' Pricking a child's finger for a drop of
blood would constitute a minimal risk, by this definition, since it is
18. Research Involving Children: Report and Recommendations of the National
Commission for the Protection of Human Subjects of Biomedical and Behavioral Re-
search, 43 Fed. Reg. 2084 (1978).
19. The Regulations are codified as: Additional Protections for Children Involved as
Subjects in Research, 45 C.F.R. § 46.401-409 (1986).
20. 45 C.F.R. § 46.404 (1986).





routinely done at physical examinations; drawing a large amount of
blood would not meet the definition.
The Regulations do not offer a definition of "material risk" either.
A material risk of harm to a child subject should certainly include
any procedure that, although not physically harmful, may frighten
or upset the child. Psychological tests that involve misleading or
deceiving a child may also be found to constitute a serious risk to
some children and may be ethically deplorable for all. In addition,
any genuine pain, as opposed to momentary minor discomfort, to a
child clearly constitutes harm.
B. "Anticipated Benefit" Projects
If an intervention or procedure holds out the prospect of direct
benefit for the individual subject, HHS will approve research that
leaves the child open to more than a minimal risk only if three con-
ditions are met: (1) the risk is justified by the anticipated benefit to
the subjects; (2) the relation of the anticipated benefit to the risk is
at least as favorable to the subjects as that presented by available
alternative approaches; and (3) adequate provisions are made for
soliciting the assent of the children and permission of their parents
or guardians.
22
In using the terms "permission" and "assent," instead of "con-
sent," the Commission clarified legal nuances that are often mis-
used, particularly by lawyers. "Consent" is an active, compre-
hending agreement, always on one's own behalf and never on behalf
of another. "Assent" has two quite separate meanings. When a per-
son who is legally capable of giving consent gives assent instead, the
word means passive acquiescence-a "going along with." 23 The
22. 45 C.F.R. § 46.405 (1986). The Commission abandoned the term "consent" to
research except in those situations in which an autonomous adult may make decisions
on his or her own behalf. In its discussions of research on children, the Commission
instead used the term parental or guardian "permission." It concluded that the "as-
sent" of the child, if he or she is old enough to give it, should also be obtained with a
form analogous to the consent form used for adult subjects. See generally Ackerman,
Moral Duties of Investigators Toward Sick Children, 3 IRB: A Review of Human Sub-
jects Research [hereinafter IRB] 1 (June/July 1981); Schoeman, Children's Competence
and Children's Rights, 4 IRB 1 (june/July 1982); Weithorn, Children's Capacities to
Decide About Participation in Research, 5 IRB 1 (Mar./Apr. 1983); Keith-Spiegel, Chil-
dren and Consent to Participate in Research, in Children's Competence to Consent
(G.B. Melton, G.P. Koocher & M.J. Saks eds. 1983) for discussions of children's rights to
make decisions in the research context.
23. See Levine, The Nature and Definition of Informed Consent in Various Research
Settings, in The National Commission for the Protection of Human Subjects of Biomedi-
cal and Behavioral Research, The Belmont Report: Ethical Principles and Guidelines for
the Protection of Hurtan Subjects of Research (Appendix, Volume I) 3-6, DHEW Publi-
cation No. (OS) 78-0013 (1975).
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second meaning of assent is more relevant to the Commission's rec-
ommendations: agreement by a person who is perhaps only techni-
cally incapable of giving a legally valid consent. A person who is not
legally capable of giving "consent" may in fact give fully informed,
active agreement. Just as a 25-year-old competent person may give
consent to a medical researcher to draw a blood sample, an intelli-
gent 12-year-old may understand just as clearly why the researcher
wishes to draw the blood, may realize just as completely that it will
produce momentary discomfort, and may wish just as actively to
agree. Because the legal system holds that children as a class, with-
out regard to individual capacity to understand, are ruled incapable
of consent, the 12-year-old's agreement is termed "assent."
C. More Risky Projects
In some circumstances, HHS will conduct or fund research where
more than minimal risk to children is presented by an intervention
or procedure that does not hold out the prospect of direct benefit
for the individual subject or by a monitoring procedure that is not
likely to contribute to the wellbeing of the subject. This process will
only be approved if an IRB finds that: (1) the risk represents a mi-
nor increase over minimal risk; (2) the intervention or procedure
presents experiences to subjects that are reasonably commensurate
with those inherent in their actual or expected medical, dental, psy-
chological, social, or educational situations; (3) the intervention or
procedure is likely to yield generalizable knowledge about the sub-
jects' disorder or condition that is of vital importance for the under-
standing or amelioration of the subjects' disorder or condition; and
(4) adequate provisions are made for soliciting assent of the chil-
dren and permission of their parents or guardians.2 4
The definition of "a minor increment over minimal risk" is left to
the discretion of the IRB reviewing the research study. The IRB at
Yale University, for example, has approved bone marrow aspira-
tions in adolescent leukemia victims, who are already familiar with
the procedure, and single spinal taps on those adolescent patients
who have already experienced the procedure during diagnostic eval-
uations for various illnesses. The IRB would not permit such an
intervention on healthy children or pre-adolescent patients.
HHS will also conduct or fund research that the IRB does not
believe meet other regulatory requirements if:




(1) the IRB finds that the research presents a reasonable oppor-
tunity to further the understanding, prevention, or alleviation of a
serious problem affecting the health or welfare of children; and
(2) the Secretary of HHS, after consultation with a panel of ex-
perts in pertinent disciplines (such as science, medicine, education,
ethics, and law) and after opportunity for public review and com-
ment, has determined either that:
(a) the research in fact satisfies the conditions of other regu-
latory sections, or
(b) the proposed research will meet the following three
tests:
(i) the research presents a reasonable opportunity to
further the understanding, prevention, or alleviation of a
serious problem affecting the health or welfare of children;
(ii) the research will be conducted in accordance with
sound ethical principles; and
(iii) adequate provisions are made for soliciting the as-
sent of children and the permission of their parents or
guardians.
2 5
Unfortunately, HHS did not renew the charter or funding of the
panel of experts in related fields, known as the Ethics Advisory
Board, when they expired in 1980.26 As a result, no mechanism ex-
ists today for approval of federal funding for studies involving more
than minimal risk, and no such studies are funded.
D. Responsibilities of the IRBs
The Regulations often require IRBs to determine that adequate
provisions are made for soliciting the assent of competent children.
In determining whether children are capable of assenting, an IRB
must take into account the age, maturity, and psychological state of
the children. This judgment may be made for all children involved
in research under a particular protocol, or on an individual basis. If
the IRB determines that: (1) the capability of some or all of the
children is so limited that they cannot reasonably be consulted, or
(2) the intervention or procedure involved in the research holds out
a prospect of direct benefit that is important to the health or wellbe-
ing of the children and is available only in the context of the re-
25. 45 C.F.R. § 46.407 (1986).
26. R.J. Levine, Ethics and Regulation of Clinical Research 319 (2nd ed. 1986).
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search, the assent of the children is not a necessary condition for
proceeding with the research.
2 7
Under the Regulations, the IRB must make adequate provision
for soliciting the permission of each child's parents or guardians.
Under 45 C.F.R. §§ 46.404 and 46.405, the IRB may find that per-
mission of one parent is sufficient for research. Where research is
covered by §§46.406 and 46.407 and permission must be obtained
from parents, both parents must give their permission unless one
parent is deceased, unknown, incompetent, or not reasonably avail-
able, or only one parent has legal responsibility for the care and
custody of the child.
If an IRB determines that a research protocol is designed for a
subject population for which parental or guardian permission is not
a reasonable requirement (for example, neglected or abused chil-
dren), it may waive the consent requirements, provided an appropri-
ate mechanism for protecting the children is substituted. For
example, the IRB may appoint one of its members to interview the
child and make an independent determination that the child wishes
to participate. The choice of an appropriate mechanism depends on
the nature and purpose of the activities described in the protocol,
the risk and anticipated benefit to the research subjects, and the
children's age, maturity, status, and condition.
Children who are wards of the state or any other agency, institu-
tion, or entity can be included in research approved under 45 C.F.R.
§§ 46.406 or 46.407 if the research is: (1) related to their status as
wards, or (2) conducted in schools, camps, hospitals, institutions, or
similar settings in which the majority of children involved as sub-
jects are not wards. If the research meets these requirements, the
IRB must appoint an advocate for the best interests of the child.
One individual may serve as advocate for more than one child; the
advocate must be unrelated to the research group or the guardian
agency. 28 This section serves to protect children who are available
in public institutions and whose families may or may not be situated
to consider their participation. If parents whose children live at
home allowed them to participate in a particular research project,
this section would permit institutionalized children to participate in
the project.
27. 45 C.F.R. § 46.408 (1986).




III. Analysis of Parental Consent
Section 46.408 of the Regulations sensibly relies on parental per-
mission as an important protection for children who are research
subjects. As a matter of public policy, it is difficult to argue that a
parent should be denied the right to consent to his or her child's
participation in even harmless research. There are thousands of
harmless procedures that provide valuable and necessary informa-
tion when performed on normal children as controls for research.
Examples of such research include noninvasive procedures like psy-
chological or intelligence tests, physical examinations, regulation of
diet (so long as the child is not deprived of necessary nutrition), and
studies of urine or blood samples. Society should be willing to per-
mit parents to accept the relatively low risks involved in this type of
research, which is necessary to improve the medical treatment of
children.
The daily lives of any normal children include many physically
risky activities. Yet no one questions the right of a parent to consent
to his or her child's participation in such normal activities as, for
instance, riding a bicycle in a city or climbing mountains in an Out-
ward Bound program. In fact, some child custody cases indicate
that a parent who prevents a child's participation in normal activities
in order to shelter the child from injury or germs is likely to lose
custody on the ground that such overprotection is harmful to the
child.29 The ironic extension of the anti-research logic is that while
a parent may consent to a child's participation in football, which
might result in a variety of serious injuries or even death, that same
parent has no authority to allow that child to have a blood sample
drawn by a physician if the blood will be used in research of no di-
rect benefit to the child.
Given the necessity of experimental controls for successful re-
search, a competent parent should be able to consent to research so
long as the risk of harm to the child is less than that to which a child
of that age is reasonably likely to be exposed in daily life. To return
to the football analogy, if participation is encouraged because the
child learns sportsmanship and other values, a child who is en-
couraged to donate a small sample of blood for the benefit of other
children may be learning altruism and empathy.
29. Holder, Mental Illness and Parental Rights, 216 JAMA 575, 576 (1971) (citing
Ericson v. Ericson, 195 P. 234 (Wash. 1921) (holding that a mother's refusal to let her
children play outside is one ground requiring rehearing of petition claiming she was
unfit)).
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This is not to suggest that parents must consent to their children's
participation in all harmless research procedures. Parents retain the
right to withhold consent, as they may not agree with the purpose of
the research. The possibility of a disagreement with the purpose of
the study, even though the child would obtain a direct benefit, might
well arise in some psychological, sociological, or behavioral research
projects. For example, research on children who have reading disa-
bilities could conceivably benefit the particular child-subject, but the
data might also be used to "prove" that the child's social or ethnic
group is inferior or superior to other groups in reading aptitude as
well as achievement. Recent studies, for example, indicate that
comparing mathematical aptitude levels of boys and girls "proves"
that boys are clearly superior to girls in mathematical reasoning
abilities.30 Many women's groups objected to the research that led
to this conclusion as biased.
When parental permission is requested for comparative studies of
children based on hypotheses that one group may be superior or
inferior to another in some respect, the purposes of the studies must
be explained to parents. The potential uses of an investigation may
be of equal or greater concern to parents than the immediate benefit
that they hope will accrue to their child from it, and they should be
permitted to refuse their permission.
The Regulations on the elements of informed consent to research
of course include the right to refuse to participate. 3' Although there
have not yet been any cases on the subject, the following situation
may arise at any time: A child has a disease, such as leukemia or
bone cancer, and her parents wish to reject standard medical ther-
apy and have her take laetrile or another substance. Welfare offi-
cials obtain a court order to have the child treated.3 2  Standard
30. See, e.g., Benbow & Stanley, Sex Differences in Mathematical Reasoning Abilily:
More Facts, 222 Science 1029 (1983).
31. 45 C.F.R. § 46.116 (1986).
32. All state courts interpret willful refusal to provide a child with necessary medical
care as a violation of child neglect laws. "Neglect" may include failure to take a sick
child to the physician, see, e.g., In re Tolbert, 378 N.E.2d 565 (Ill. 1978) (children re-
moved from mother's care because they suffered from untreated malnutrition and worm
infections); In re D.L.E., 645 P.2d 271 (Colo. 1982); and In re Hamilton, 657 S.W.2d
425 (Tenn. 1983); failure of parents for religious reasons to permit children to receive
blood transfusions during necessary surgery, see, e.g., Jehovah's Witnesses of Washing-
ton v. King County Hospital, 390 U.S. 598 (1968); Muhlenberg Hospital v. Patterson.
320 A.2d 518 (N.J. 1974); In re Sampson, 278 N.E.2d 918 (N.Y. 1972); and Holder,
Circumstances Warranting Court-Ordered Treatment of Minors, 24 Proof Of Facts 2d
169 (1980); a wish to use laetrile or some other medically unaccepted remedy, see, e.g.. In
re Custody of a Minor, 379 N.E.2d 1053 (Mass. 1978), aff'd, 393 N.E.2d 836 (Mass.




therapy fails. The physician caring for the child wishes to use an
investigational drug that is on a protocol pending approval by the
Food and Drug Administration. The parents, still adamant in their
opposition to the administration of chemotherapy, refuse permis-
sion fbr the child to enter the study. The physician asks the judge to
order it. There is no medical disagreement that the drug might
cause a remission or that the child would die without it. Yet under
the Regulations, so long as parents have custody of the child, they
have the right to refuse administration of an investigational
substance.
Forced participation in a drug trial asks the unwilling adolescent
patient or parent of a child patient to assume the risks of unknown
side effects or other problems with the drug. Since there is always a
risk that an investigational substance will not work as well as stan-
dard therapy, no parent should ever be required to permit his or her
child to participate in any research.
If' Analysis of Children's Assent
Although the Commission report recommended that children be
given a "right to dissent" from participating in research that would
not directly benefit them, the final version of the Regulations did
not include such a provision. The omission is a surprising and dis-
turbing one, in light of the recognition of children's rights in other
areas. For instance, although the Supreme Court has recognized a
teacher's right to spank a misbehaving child, it also has held that the
discomfort must be administered in a manner that does not violate
minimal constitutional guarantees of due process.3 3 For instance,
the child has a right to protest the administering of a physical pun-
ishment before it takes place. 34 Adopting this principle in a re-
search context, any child who is to be subjected to any discomfort in
a nontherapeutic context should have a clear right to object to par-
of Wachlin, 245 N.W.2d 183 (Minn. 1976) (child with neurological disfunction found to
be neglected because mother refused to cooperate with efforts to provide speech ther-
apy).
Most cases in which courts order treatment involve life-threatening illnesses, but
courts have gone so far as to order treatment when its absence would cause permanent
psychological disability. See, e.g., In re Sampson, 278 N.E.2d at 918. Courts will not
intervene, however, when parents are taking a child to a licensed physician and comply-
ing with his or her instructions, even if most other physicians and/or the public welfare
department disagree with the physician's views. See, e.g., In re Hofbauer, 393 N.E.2d
1009 (N.Y. 1979): In re Doe, Order by Circuit Court for Monroe County, Indiana, No.
GU-8294-004A (Apr. 12, 1982) (reprinted at 47 Conn. Med. 409 (July 1983)).
33. Baker v. Owen, 395 F. Supp. 294, af'd, 423 U.S. 907 (1975).
34. 395 F. Supp. at 302.
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ticipation. "I don't want to be stuck with a needle" should be a suf-
ficient objection.
If the child agrees to a minor discomfort once it has been ex-
plained, if he or she is not afraid, and if the parents concur, such an
intervention is-and should be-legally permissible. Since adults
have the right to refuse to participate as a research subject for any
reason, and since children deserve the same respect that researchers
accord an adult, a child's withholding of assent should also suffice to
eliminate his or her participation as a research subject where he or
she will not directly benefit. While the IRBs retain discretion to re-
quire investigators to respect children's refusals, it would seem that
the Regulations should be amended to allow such dissents.35 Where
the child is too young to communicate, the parent alone may with-
hold consent.
V. Adolescent Assent or Consent?
The murky legal status of adolescents-i.e., should the courts
treat them as children or as adults?-has posed special problems in
determining their capacity to consent to participation in research.
Similarly, it poses problems in determining their capacity to consent
to medical treatment. During the past few decades, courts have sub-
stantially broadened the right of adolescent patients to consent to
medical treatment without parental knowledge.36 Even in the ab-
sence of specific treatment statutes permitting adolescents to con-
sent, courts in all states have adopted what is known as the "mature
minor rule." This jurisprudential doctrine permits teenagers who
are capable of understanding a procedure and its risks to give in-
formed consent in the same way that adult patients do. Teenagers
in all states may make their own health care decisions, at least where
the procedure can be characterized as "minor" in nature.
37
In the relatively few cases in which the issue of a minor's refusal of
treatment has been litigated, courts have held that if a minor has the
35. In some cases, treatment for the child's medical problem is only possible within a
study designed to determine the safety or efficacy of a non-validated practice. A child
may, for example, have a disease for which the only possible treatment is a drug on
investigational status. In this case, the legal rules applying to the limitations of a minor's
rights to refuse treatment in the context of medical practice should be applied.
36. See A. Holder, Legal Issues in Pediatric and Adolescent Medicine (1985) (Chap-
ter Five); Holder, Minors' Rights to Consent to Medical Care, 257 JAMA 3400 (1987).
37.. Pilpel, Minors' Rights to Medical Care, 36 Alb. L. Rev. 462 (1972); Wadlington,
Minors and Health Care: The Age of Consent, II Osgoode Hall L.J. 115 (1973); Mun-
son, Toward A Standard of Informed Consent by the Adolescent in Medical Treatment
Decisions, 85 Dick. L. Rev. 431 (1981); Ewald, Medical Decisionmaking for Children: An




right to consent to treatment, he or she has the right to refuse it.38
The question of whether to extend a mature minor's right, without
permission of his or her parents, to consent to treatment to the right
to consent to minimal-risk research is one that has engendered
much debate among lawyers and ethicists since the Commission's
report was issued. 39 Section 46.408(c) of the Regulations does ex-
tend adolescents' right to consent, dispensing with the necessity of
parental permission for participation in research equivalent to most
treatment interventions for which the adolescent may consent.
Although the Regulations provide that prior parental approval re-
quirements may be waived when such permission is not a reasonable
requirement for the protection of subjects, the scope of this waiver
has yet to be defined. No IRB is likely to waive permission for any
research involving more than minimal risk of physical harm.
Under § 46.408(c) of the Regulations, the IRB must make judg-
ments about waiving parental permission requirements in four situ-
ations in which questions about participation by adolescents in
research typically arise.
(1) Adolescence is relevant to the condition studied. An example would
be a survey of attitudes of teenagers who have had abortions. In this
context, not only would it be an imposition on a teenager whose
parents did not know that she had had an abortion to get their per-
mission to ask her questions about it, but she would undoubtedly
decline to participate in the survey on this basis. Requiring parental
permission to participate in such a survey would run counter to the
purpose of the Regulations that permission be Sought for the pro-
tection of subjects. These adolescents have already exercised their
right to choose an abortion. Forbidding them to decide indepen-
dently whether they want to answer questions about this decision
illustrates the potential for these Regulations to be read in an over-
protective manner. It certainly seems appropriate to dispense with
parental permission in these cases.
(2) Adolescence is irrelevant to the research. For instance, a medical
researcher posts notices in undergraduate dormitories that he or
38. Since a younger child cannot consent and may only assent, he or she presumably
also lacks the right to refuse. A parent might give permission for research activities for a
small child receiving investigational chemotherapy even if the child objected. See, e.g., In
re Smith, 295 A.2d 238 (Md. 1972); Melville v. Sabbatino, 313 A.2d 886 (Conn. 1973);
In re Mary P., 444 N.Y.S.2d 545 (1981).
39. See Holder, Can Teenagers Participate in Research Without Parental Consent?, 3
IRB 5 (Feb. 1981); Herceg-Baron, Parental Consent and Family Planning Research In-
volving Minors, 3 IRB 5 (Nov. 1981); Levine, Teenagers, Research, and Family Involve-
ment, 3 IRB 8 (Nov. 1981).
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she will pay research subjects five dollars to donate a tube of blood.
One of the volunteers is a 16-year-old freshman. Most IRBs would
waive parental permission only where there is little or no risk
involved.
(3) The research involves an attempt to recruit subjects from a variety of
age groups. For example, a political scientist wishes to survey a vari-
ety of people in the community to find out how many of them recog-
nize the Bill of Rights. She wants to include a group of 16-year-old
"candy stripers" at the local hospital. If the information is not par-
ticularly sensitive, there seems no reason to require parental per-
mission before it can be solicited.
(4) The research is not related to the patient's age, but an adolescent pa-
tient has a disease that a clinical researcher wishes to study or an investiga-
tional drug that the researcher wishes to prescribe. For example, a
hematologist treating a 16-year-old who has leukemia that is not re-
sponsive to standard therapy wishes to enroll the adolescent in a
protocol for an investigational drug. Investigational therapy with a
risk of serious side effects is reserved for conditions that are them-
selves serious, regardless of the patient's age. Since it is not very
likely that a teenager with leukemia is being treated without parental
knowledge, protocols of this sort are most unlikely to present an
ethical issue of a waiver of parental permission. If they do, however,
parental permission should almost always be required, due to the
great risk of side effects from the investigational drug.
An IRB's decisions in these four situations must be based on its
interest in protecting the adolescent subject. Any waiver of parental
permission must also be accompanied by the enactment of a substi-
tute mechanism for the protection of the adolescent subjects. As
the above examples show, interpretation of § 46.408(c) requires
flexibility on the part of the IRB. The board must be sensitive to
research needs as well as to the dangers of too much or too little
protection of adolescent subjects. Protection mechanisms should
reflect these considerations.
VI. Exempted Psychological Research
In one area, the Regulations may not go far enough. Research in
schools involving normal educational practices, such as studies of
the effectiveness of instructional techniques or classroom manage-
ment methods, are often exempted under the HHS regulations from
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IRB review and from any. parental permission requirements:"'
While requiring IRB review and/or parental permission for research
in the classroom might be unnecessary in most cases, such review or
parental consent may be vital for some psychological research re-
quiring children to be asked personal questions about themselves or
their families that may violate customary standards of privacy.
4 1
The psychological research exception should be narrowed.
The results of such research may harm children as well as violate
family privacy. Classification of children who are research subjects
by labels such as "gifted," "slow," "hyperkinetic," "depressed," or
"uncoordinated," may be entered on school records and follow the
children throughout their educational careers. 42 Unproven test in-
struments, which may provide inaccurate results, have the potential
for even greater harm to children who are the subjects of this re-
search. Although HHS may have exempted educational research
from consent and review requirements on the ground that it is in-
nocuous, this sort of research may be potentially far more damaging
to a child than a minimal-risk activity conducted in the context of
biomedical research. It should be covered by consent and review
requirements in the same manner as medical research.
VII. Child Research Abuse: 4 False Threat
Although there is a potential for child abuse in research as in
other settings, reported cases of such exploitation are now rare.
Medicine's view of children has changed since 1722, when Queen
Caroline ordered an experimental smallpox vaccination program for
10 orphans to see what would happen before she would consent to
vaccinating the royal offspring. 43 The work of the Commission and
the Regulations that resulted have encouraged safer pediatric re-
search, particularly in the area of drug development, than ever
before.
One recent study demonstrates the current cautious approach to-
ward pediatric research. Researchers who sought to study certain
mechanisms of diabetes in the healthy siblings of children with the
40. 45 C.F.R. § 46.101(b)(1) (1986).
41. Merriken v. Cressman, 364 F. Supp. 913 (D.Pa. 1973); Sherrer & Roston, Some
Legal and Psychological Concerns About Personality Testing in Public Schools, 30 Fed.
B.J. II1 (Spr. 1971).
42. Kirp, Schools as Sorters: The Constitutional and Policy Implications of Student
Classification, 121 U. Pa. L. Rev. 705 (1973).
43. Mitchell, The Child and Experimental Medicine, I Brit. Med.J. 721, 722 (1964);
Moros, The Philosophy of Medicine: Clinical Science and Its Ethics, 31 IPersp. in Biology
& Med. 134 (1987).
155
Yale Law & Policy Review
disease needed to identify changes in their blood glucose levels. 44
The healthy children were to be admitted to the hospital for 48
hours to allow blood to be drawn at frequent intervals. (Only one
needle stick was required, and blood was drawn thereafter without
discomfort.)
The IRB that reviewed the study was very concerned about the
effects of hospitalization on healthy children. After exhaustive dis-
cussion, it approved the protocol. The researchers discovered that
the children were made uncomfortable by the IV boards, so they
removed the boards. The worst problem thereafter was boredom,
since the children were effectively immobilized by the IV lines. Be-
cause no one wished to continue a study on bored or unhappy chil-
dren, a VCR was brought onto the pediatric research unit. The only
harm from the study was reported to be to the researchers' sanity-
in their efforts to protect the children, they had to suffer through
repeated showings of Raiders of the Lost Ark. Such are the "dangers"
of pediatric research as it is being conducted today.
Conclusion
It is unfortunate that many politicians, journalists, and some phy-
sicians still equate pediatric research with abuse. Pediatric research-
ers and drug companies who fail to appreciate the extent of the
research permitted under, and the protections offered by, existing
government regulations are afraid to commit funding and reputa-
tions to research that still inspires fear and prejudice. Progress in
gaining knowledge of children's diseases and potential treatments is
slowed as a result. Protection of the rights of children participating
in medical research is vitally important, but ironically, the overcau-
tion prevalent in research institutions today hurts children's inter-
ests more than it protects them.
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